• Gilead announces phase I trials of an inhalable formulation of remdesivir,and plans to test it in people with COVID-19 by August. Source
• Glenmark issues a press release with top-line results from its 150-person phase III trial of favipiravir in people with mild-to-moderate COVID-19. Study participants were treated within 48 hours of a positive viral load test with standard supportive care, with or without favipriavir for up to 14 days. People who received favipiravir were significantly more likely to be cured by day 4; no serious adverse events were reported although the drug has been known to cause liver enzyme abnormalities, gastrointestinal symptoms, and serum uric acid elevations. Sources 1,2
